Another treatment option for severe OAK has also recently shown to be of minor benefit: arthroscopy. It was mentioned in the NY Times last week. This builds the case for additional pain (and eventually, regenerative) options.
The study reviewed 9 trials, 1270 patients, age 50-62 with knee pain and knee degeneration. WOMAC VAS scale readout. BMJ 2015;350:h2747
Bottom Line: "The small inconsequential benefit seen from interventions that include arthroscopy for the degenerative knee is limited in time and absent at one to two years after surgery. Knee arthroscopy is associated with harms. Taken together, these findings do not support the practise of arthroscopic surgery for middle aged or older patients with knee pain with or without signs of osteoarthritis."
100mm VAS: "15-20 mm commonly suggested as representing a clinically relevant difference for pain"
"Available evidence supports the reversal of a common medical practice. However, disinvestment of commonly used procedures remains a challenge, and use of arthroscopy seems to be undiminished, in analogy with use of vertebroplasty following the publication of trials showing absence of benefit of this procedure. Surgeon confirmation bias in combination with financial aspects and administrative policies may be factors more powerful than evidence in driving practice patterns"
True. And it happened on 2 different statement releases. Sloppy. So, if a date is mentioned at all from these firms it's 7/7, for whatever reason. The good news is that the nonsense will expire next Tuesday.
Did anyone notice the change in date for a lead plantiff by Levi & Korsinsky? Originally Aug 10, now Jul 7. Wonder if that's a sign of desperation, competition among firms, or something else.
They all date back to STEP and claim the company withheld info about shipping the drug at too low T. Obviously ridiculous, since the company would not willingly jeopardize their own trial. There was one instance of suspected freezing at one site and the drug was reshipped immediately.
Hi hubby,, Even without the Real Imbecile littering the board with his infantile drivel there is still plenty of BS still posted
I did almost the exact same thing at 2.55. Oh well... In MM we trust? May a higher power help us. I still believe in the product and I can't help but be optimistic on a rolling BLA along with the due diligence of the big pharma already completed. The mfg facility already built and I think approved.. (right?) There's too much here to be a no show on the revenue or acquisition front.
I just came across this company. I like the product prospects of the product option. I see much controversy around this company. Please give me insight. Is the company legit. Are these products on track for going to market. Or is this some phony pump and dump machine.
With Greece going bankrupt and Puerto Rico threatening to follow events may overtake us and render all other outstanding issues moot. I'm anticipating a market meltdown as people start to realize the unimaginable is imaginable and lose confidence in all public debt when they realize that Detroit was the canary in the mine and simply the precursor to the failure of a lot of municipal debt as over promised public pensions become due and the promises are found to be empty. The financial shet is about to hit the proverbial fan, IMHO.
A buncha Chicken Little Nostradamus' in here these days. Have a little more patience guys a do some research. Quit relying on BW to provide you with information.
Sentiment: Strong Buy
"It has been clear for a long time that his comments are cleverly disguised to evoke negative perceptions about Ampio, " LOL, As if the current share price and disappointing trials wasn't doing that already. Pollyanna has nothing on you Rac your seemingly irrational optimism is eroding your credibility
"It's simple. We know BP had an offer on the table. I have heard it was in the $30 range as a starting point."
How do we know that? I must have missed the news flash
Abbreviations are sometimes not as obvious as they might seem. Big Pharma.
However, it could be a well funded biotech too. Big Pharma is usually interpreted as the goliaths (Pfizer, Merck, Lilly, GSK, BMS...). It's highly likely some experienced set of scientists and patent lawyers performed due diligence/DD to get to a term sheet, which is likely where they were pre-STRIDE completion, per MM's conference call/CC comments. I don't know about the $30 figure, but would be exceptionally happy if that *were* the case. Right now, I'd be fine with $15! GTLA
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. reported today top line results from the double-blind, placebo-controlled Phase 2b study designed to evaluate the safety and efficacy of topically applied TV-45070 (4% and 8% w/w ointment) in patients with chronic pain due to osteoarthritis (OA) of the knee.
TV-45070 is a small molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. Results from this trial showed that TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints of reductions in pain due to OA.